NEW YORK, March 29, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on AGN, CPRX, FLXN, and SUPN which can be accessed for free by signing up to www.wallstequities.com/registration. Featured on WallStEquities.com is the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic.  The cost-effectiveness of generic drugs has given it a competitive advantage over branded drugs in the market. In this morning's lineup are: Allergan PLC AGN, Catalyst Pharmaceuticals Inc. CPRX, Flexion Therapeutics Inc. FLXN, and Supernus Pharmaceuticals Inc. SUPN. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Allergan

On Wednesday, shares in Dublin, Ireland headquartered Allergan PLC recorded a trading volume of 3.79 million shares, which was above their three months average volume of 3.38 million shares. The stock ended at $165.65, rising 3.32% from the last trading session. The Company's shares have gained 3.59% in the last month and 0.74% over the previous three months. The stock is trading below its 50-day moving average by 0.69%. Furthermore, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 52.14. 

On March 22^nd, 2018, Allergan announced the launch of Ozurdex^® (dexamethasone intravitreal implant 0.7 mg) in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion (RVO). RVO is the second most common type of retinal vascular disorder after diabetic retinal disease, and it is estimated that 7.4 million people in China are living with the condition. Get the full research report on AGN for free by clicking below at:

www.wallstequities.com/registration/?symbol=AGN

Catalyst Pharmaceuticals

Coral Gables, Florida-based Catalyst Pharmaceuticals Inc.'s stock finished yesterday's session 0.40% higher at $2.51. A total volume of 993,646 shares was traded, which was above their three months average volume of 634,640 shares. The Company's shares have gained 32.11% over the past year. The stock is trading below its 200-day moving average by 18.71%. Furthermore, shares of Catalyst Pharma, which focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, have an RSI of 26.75. 

On March 14^th, 2018, Catalyst Pharma reported its results for Q4 and year ended December 31^st, 2017. For Q4 2017, GAAP net loss was $(5,387,698); research and development (R&D) expenses were $3,404,634; and general and administrative (G&A) expenses totaled $2,107,152. For the full year, GAAP net loss was $(18,412,377); R&D expenses were $11,375,237; and G&A expenses totaled $7,304,399. The free technical report on CPRX can be accessed at:

www.wallstequities.com/registration/?symbol=CPRX

Flexion Therapeutics

At the close of trading on Wednesday, shares in Burlington, Massachusetts headquartered Flexion Therapeutics Inc. dropped 5.61%, ending the day at $21.69. The stock recorded a trading volume of 1.40 million shares, which was above its three months average volume of 742,000 shares. The Company's shares are trading 8.77% below their 200-day moving average. Moreover, shares of Flexion Therapeutics have an RSI of 36.52. 

On March 02^nd, 2018, Flexion Therapeutics announced a grant of inducement stock options to two new employees for an aggregate of 4,000 shares of common stock. The Compensation Committee of the Board of Directors approved the grants, with an effective date of March 01^st, 2018. The stock options have an exercise price of $25.16 per share, and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Sign up for free on Wall St. Equities and claim the latest report on FLXN at:

www.wallstequities.com/registration/?symbol=FLXN

Supernus Pharmaceuticals

Rockville, Maryland-based Supernus Pharmaceuticals Inc.'s shares ended the day 1.44% higher at $45.80. A total volume of 730,537 shares was traded, which was above their three months average volume of 706,210 shares. The stock has gained 20.21% in the last month, 17.59% over the previous three months, and 48.46% over the past year. The Company's shares are trading 10.39% above their 50-day moving average and 10.48% above their 200-day moving average. Additionally, shares of Supernus Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the US, have an RSI of 64.45.  See the free research coverage on SUPN at:

www.wallstequities.com/registration/?symbol=SUPN

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: +21-32-044-483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-generic-drugs-stocks----allergan-catalyst-pharma-flexion-therapeutics-and-supernus-pharma-300621565.html

SOURCE Wall St. Equities